Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
Publishing timestamp: 2024-06-03 09:23:27
Summary
GSK shares plunged after Delaware State Court ruled that scientific evidence can be presented in cases relating to discontinued heartburn drug Zantac, which has been linked to a probable carcinogen. Pharmaceutical firms deny the link to cancer and plan to appeal the decision. Multiple companies are involved in the lawsuits, with potential settlement costs reaching billions of dollars.
Sentiment: MIXED
Keywords: pharmaceuticals, breaking news: markets, gsk plc, health care industry, world markets, markets, sanofi sa, business news,
Source: https://www.cnbc.com/2024/06/03/gsk-plunges-after-us-court-makes-zantac-ruling.html